Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Tom Wei-Wu ChenWen HsiaoMing-Shen DaiChing-Hung LinDwan-Ying ChangI-Chun ChenMing-Yang WangShu-Han ChangShu-Min HuangAnn-Lii ChengKo-Wen WuKien Thiam TanYen-Shen LuPublished in: Breast cancer research and treatment (2023)
After adjustment of cfDNA level, PIK3CA and TP53 mutations observed in liquid biopsy exerted detrimental effects on the outcome of ET-based regimens. The AF of PIK3CA or TP53 may be a surrogate marker for PFS.